Arcadia Investment Management Corp MI Sells 1,205 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Arcadia Investment Management Corp MI lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,066 shares of the medical research company's stock after selling 1,205 shares during the period. Thermo Fisher Scientific makes up about 2.8% of Arcadia Investment Management Corp MI's portfolio, making the stock its 11th largest holding. Arcadia Investment Management Corp MI's holdings in Thermo Fisher Scientific were worth $15,458,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TMO. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock valued at $17,297,426,000 after buying an additional 196,864 shares in the last quarter. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after buying an additional 104,343 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after buying an additional 197,442 shares in the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $3,149,754,000. Finally, Northern Trust Corp raised its position in shares of Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after buying an additional 455,004 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on TMO shares. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $601.05.

Thermo Fisher Scientific Trading Up 2.6%

Shares of NYSE:TMO traded up $10.74 during trading on Thursday, reaching $430.62. The stock had a trading volume of 1,361,915 shares, compared to its average volume of 1,985,118. The firm's fifty day moving average is $408.93 and its 200 day moving average is $477.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The stock has a market cap of $162.56 billion, a price-to-earnings ratio of 25.25, a P/E/G ratio of 2.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm posted $5.11 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.